• Technology and Data
  • Front End Sales and Marketing
  • Allergy
  • HIV
  • Women's Health
  • Migraine
  • Compounding
  • Continuous Glucose Monitoring
  • Mental Health Awareness
  • Veterinary Pharmacy
  • CBD
  • Infectious Disease
  • Eye Health
  • Digestive Health
  • Biosimilars
  • Influenza
  • Shingles
  • COPD Management
  • Pediatrics
  • Generics
  • Pain Management
  • COVID-19
  • Immunization
  • Oncology
  • Anticoagulants
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Respiratory
  • Heart Health
  • Cardiovascular Clinical Consult

Latebreakers: Orphan drug acromegaly treatment wins FDA approval

Article

Somatuline Depot receives FDA approval for the treatment of acromegaly.

Lanreotide acetate injection (Somatuline Depot, Beaufour Ipsen/ Tercica) has been approved by the FDA for the long-term treatment of acromegaly, a disease characterized by abnormal secretion of growth hormone. The drug works by lowering levels of growth hormone and insulin-like growth factor-1, which stimulate bone and tissue growth and lead to enlargement of hands, feet, internal organs, and facial bones in patients with the disease. Lanreotide is administered as a subcutaneous injection once every four weeks for three months and will be available as 60-, 90-, and 120-mg prefilled syringes in about eight weeks, according to the manufacturer. The new treatment is indicated for patients who have not responded well to or are not candidates for surgery and/or radiotherapy.

Related Videos
fake news misinformation | Image Credit: Bits and Splits - stock.adobe.com
© 2023 MJH Life Sciences

All rights reserved.